Floatz logo

RAMIFENTANYL

Ketamine

Evangelismos HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Ketamine cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB
Vts-K
Theresa Jacob, PhD, MPH
Phase 4BB
LIDOCAINE
Tanta University
Phase 4BB
L-Bupivacaine
Tanta University
Phase 4BB
PROPOFOL
Evangelismos Hospital
Phase 4BB

View all 16 →

Same molecule, other indications

RAMIFENTANYL is also rated in:

morbid obesityDormant
BBB
Indicative ·
73 / 100
View asset →
cardiovascular disorderDormant
BBB
Indicative ·
73 / 100
View asset →
Anesthesia, GeneralDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →